FibroBiologics, Inc. develops fibroblast-based and fibroblast-derived therapies for chronic diseases and regenerative medicine applications. News about FBLG centers on its clinical-stage cell-therapy platform, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and related programs in wound healing, disc degeneration, orthopedics, cancer, immune aging, and pulmonary inflammatory conditions.
Company updates commonly cover clinical-trial preparation and drug-product manufacturing, preclinical data from fibroblast spheroids and thymic organoid research, scientific meeting presentations, shareholder communications, quarterly financial results, Nasdaq listing compliance, and capital-planning actions that support development of its fibroblast technology pipeline.
FibroBiologics (Nasdaq: FBLG) will participate in a RedChip-hosted investor webinar on November 19, 2026, covering its fibroblast-based cell therapy programs. CEO Pete O'Heeron and CFO Jason Davis will present at 4:15 p.m. ET, followed by live questions.
Patient dosing is underway in the CYWC628 Phase 1/2 trial for diabetic foot ulcers. The company expects enrollment of up to 120 patients and data in 2026. The study compares two doses plus standard wound care against standard care alone. For psoriasis, CYPS317 has an investigational new drug application under FDA review; a 12-week clinical study is expected following clearance. Other programs include CYMS101 for multiple sclerosis and CybroCell for degenerative disc disease.
FibroBiologics (Nasdaq: FBLG) reported that its intellectual property portfolio now includes 170 issued patents covering fibroblast therapies and manufacturing methods. Issued patents increased from 124 on December 31, 2025, while the worldwide portfolio now exceeds 325 issued and pending patents across more than 50 patent families.
U.S. patents granted in 2026 cover wound healing, type 1 diabetes, osteoporosis, cachexia and degenerative disc disease. European grants cover methods of enhancing fibroblast therapeutic activity and delivering tumor inhibitory agents. Manufacturing coverage includes three-dimensional cell clusters called spheroids, gene modification and oral delivery systems. Recent filings address injectable thymus organoids, cell aggregates that secrete therapeutic peptides and orally delivered fibroblast therapeutics.
FibroBiologics (Nasdaq: FBLG) has received a European patent covering methods for preparing fibroblast cells to deliver tumor-inhibiting agents to cancer.
European Patent EP 4454709, titled “Fibroblast Delivery of Tumor Inhibitory Agents,” covers modifying fibroblasts, connective-tissue cells, to improve their movement toward cancer cells and loading them with cancer-killing viruses. The independent claim includes conditioning the cells under low-oxygen conditions, with the tumor-targeting modification performed before, after or during loading.
Data described in the patent showed that fibroblasts carrying Newcastle disease virus significantly inhibited tumor growth in a mouse melanoma model. The virus alone did not affect tumor growth, even at high doses. The approach is intended to concentrate treatment at tumors while limiting healthy-tissue exposure.
FibroBiologics (FBLG) presented preclinical results showing its fibroblast-derived cartilage-forming cell spheroids preserved disc height in a rabbit model of degenerative disc disease.
The study compared a single injection of conventionally cultured fibroblasts, fibroblast spheroids or fibroblast spheroid-derived chondrocyte (FSdC) spheroids with a vehicle control over 12 weeks. All three treatments produced statistically significant improvements in normalized disc height index, a measure of disc height, versus controls. FSdC spheroids maintained significantly higher values than the other treatments throughout the study. At 12 weeks, the index was 80.7% versus 71.8% in controls (p<0.05), with treatment effects consistent across the lumbar levels studied. Results were presented at the North American Spine Society annual meeting on October 15, 2026.
FibroBiologics (FBLG) announced IP Australia's acceptance of a patent application covering cell blends intended to regenerate cartilage in degenerated spinal discs.
Application No. 2024200985 covers methods combining fibroblasts, cells used in connective tissue, with platelet rich plasma and components of the nucleus pulposus, the disc's gel-like core. Claims include generating cartilage-forming cells and improving aged discs using blends that reflect a disc's cellular composition before degeneration, optionally supplemented with supporting cells.
The Notice of Acceptance means examination is complete; the application is expected to proceed to grant following publication. FibroBiologics said the acceptance extends protection around its disc degeneration program, following a European patent grant covering platelet rich plasma conditioned fibroblasts weeks earlier.
FibroBiologics (Nasdaq: FBLG) has filed a U.S. patent application for cell-based technology designed to produce therapeutic peptides continuously inside the body. The application covers GLP-1, GIP and GLP-2 class peptides, among other potential medicines. It describes engineered cells grouped into spheroids or organoids, small three-dimensional structures intended to release peptides after administration.
The company envisions a single administration as a potential alternative to repeated injections or pills, rather than a demonstrated treatment benefit. The application also describes producing different peptides together at adjustable levels. Its scope extends beyond weight loss and diabetes to possible uses in gastrointestinal, autoimmune and inflammatory diseases, wound healing, tissue regeneration, hormone deficiencies, cancer and age-related conditions.
FibroBiologics (FBLG) received European Patent No. 3568465 for methods intended to enhance the regenerative activity of fibroblasts.
The granted claims cover preparing fibroblasts with platelet-rich plasma and one or more cytokines, including FGF-alpha or FGF-beta. They also cover combinations that include a TGF-beta-family cytokine. Additional claims address blood-vessel formation, known as angiogenesis, and spinal disc regeneration. FibroBiologics links the patent to its disc degeneration clinical pathway.
FibroBiologics (FBLG) closed a $0.5 million private placement on September 15, 2026, with its Chief Scientific Officer, Hamid Khoja, Ph.D. The transaction covered 298,508 shares of common stock and accompanying warrants to purchase up to 298,508 additional shares, sold at a combined price of $1.675 per share-plus-warrant unit, calculated from a $1.55 share price and $0.125 per warrant. The warrants are immediately exercisable at $1.55 per share and expire five years from issuance. Gross proceeds are intended for general corporate purposes and working capital. The unregistered securities were issued under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
FibroBiologics (FBLG) received U.S. Patent No. 12,721,866 on September 1, 2026 for therapeutic use of fibroblasts in wound healing.
The patent covers topical administration of 3D spheroid fibroblasts and fibroblast-derived materials, including extracellular vesicles and exosomes, to treat and accelerate healing of acute and chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure wounds, burns, cuts, and abrasions. Preclinical models described in the patent showed wounds treated with fibroblast spheroids and fibroblast-derived materials healed significantly faster than controls in both diabetic and non-diabetic settings.
FibroBiologics (Nasdaq:FBLG) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,716,055 covering methods for treating degenerative disc disease using fibroblast conditioned media. The patent protects approaches that stimulate fibroblasts with opioid receptor antagonists, such as naltrexone, and toll-like receptor agonists to enhance production of regenerative growth factors like EGF.
Conditioned media and components derived from these stimulated fibroblasts may be delivered directly into intervertebral discs or systemically to promote disc regeneration and stimulate proteoglycan synthesis, potentially offering a less invasive alternative to current pain management and surgical treatments. According to FibroBiologics, this patent expands its intellectual property portfolio within disc degeneration, one of its core clinical pathways, and adds to its 270+ issued and pending patents across multiple disease areas.